SHARE
COPY LINK

COVID-19

Antibody study shows just 5 percent of Spain’s population infected by coronavirus

Only five percent of Spain's population has been infected by the novel coronavirus, though that figure climbs to more than 10 percent in Madrid and areas in the centre of the country, according to a study released by the government on Wednesday.

Antibody study shows just 5 percent of Spain's population infected by coronavirus
Photo: AFP

Spain is one of the hardest hit nations in the global pandemic, with more than 27,000 deaths and around 228,600 cases confirmed by testing since the outbreak began in China late last year.

The study launched on April 27th was based on serology tests to show exposure to coronavirus and took samples from 60,000 people.   

“The study found five percent of the Spanish have been in contact with the virus, a little more than two million people,” Health Minister Salvador Illa said.

Some studies have shown that a portion of people infected by the virus will show no symptoms, but can still transmit the disease.   

The Spanish study confirmed that the virus circulated more in the centre of the country, which paid the highest price in fatalities. 

In Madrid, the rate of infection was 11.3 percent, in Barcelona it was 7.1 percent, but only 2.3 percent in Seville, according to the study.    

The Spanish government has so far released only the results of a first wave of “rapid tests” to determine the level of antibodies as a way to ascertain who has been infected.

A similar study published on Wednesday in France showed that less than 10 percent of the population had been contaminated in the Paris region and in the northeast, the two areas most affected in France. That compared with 4.4 percent nationally.

The novel coronavirus has killed at least 294,199 people since the outbreak first emerged in China last December, according to a tally from official sources compiled by AFP at 1900 GMT Wednesday.

At least 4,305,340 cases have been registered in 196 countries and territories worldwide. But those are likely only a fraction of the true number of infections because of low levels of testing.

 

 

Member comments

Log in here to leave a comment.
Become a Member to leave a comment.

COVID-19

Public Health Agency recommends two Covid doses next year for elderly

Sweden's Public Health Agency is recommending that those above the age of 80 should receive two doses of a Covid-19 vaccine a year, once in the spring and once in the autumn, as it shifts towards a longer-term strategy for the virus.

Public Health Agency recommends two Covid doses next year for elderly

In a new recommendation, the agency said that those living in elderly care centres, and those above the age of 80 should from March 1st receive two vaccinations a year, with a six month gap between doses. 

“Elderly people develop a somewhat worse immune defence after vaccination and immunity wanes faster than among young and healthy people,” the agency said. “That means that elderly people have a greater need of booster doses than younger ones. The Swedish Public Health Agency considers, based on the current knowledge, that it will be important even going into the future to have booster doses for the elderly and people in risk groups.” 

READ ALSO: 

People between the ages of 65 and 79 years old and young people with risk factors, such as obesity, diabetes, poor kidney function or high blood pressure, are recommended to take one additional dose per year.

The new vaccination recommendation, which will start to apply from March 1st next year, is only for 2023, Johanna Rubin, the investigator in the agency’s vaccination programme unit, explained. 

She said too much was still unclear about how long protection from vaccination lasted to institute a permanent programme.

“This recommendation applies to 2023. There is not really an abundance of data on how long protection lasts after a booster dose, of course, but this is what we can say for now,” she told the TT newswire. 

It was likely, however, that elderly people would end up being given an annual dose to protect them from any new variants, as has long been the case with influenza.

SHOW COMMENTS